A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RGX-501

NCT04080050 · clinicaltrials.gov ↗

UNKNOWN

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Homozygous Familial Hypercholesterolemia (HoFH)

Interventions

DRUG: Single intravenous (IV) dose of human Low Density Lipoprotein Receptor (LDLR) Gene Therapy

Sponsor

REGENXBIO Inc.